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Daunorubicin and doxorubicin but not BCNU have deleterious effects on
organotypic multicellular spheroids of gliomas
P Kaaijkl 2 D Troost2, OJ de Boer2, P Van Amstel2, PJM Bakker3, S Leenstral and DA Bosch'
Departments of'Neurosurgery, 2(Neuro)Pathology and 'Medical Oncology, Academic Medical Center, University ofAmsterdam,
Graduate school Neurosciences Amsterdam, Amsterdam, The Netherlands.
Summary In the present study organotypic multicellular spheroids (OMS) were used to study the effects of
chemotherapeutic agents on malignant gliomas. Compared with the frequently used cell line models, OMS have
several advantages with respect to the preservation ofthe cellular heterogeneity and the structure of the original
tumour. OMS prepared from seven glioma specimens were treated with 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU), daunorubicin or doxorubicin. After exposure to these drugs, the histology and cell proliferation of
the OMS were analysed by immunohistochemistry and image analysis. Furthermore, the expression of P-
glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to
daunorubicin and doxorubicin, were immunohistochemically investigated. We found that OMS from gliomas
are sensitive for daunorubicin and doxorubicin but not for BCNU in terms of tissue destruction and decrease
in cell proliferation. In addition, all gliomas were P-gp and MRP negative, which is in accordance with the
sensitivity for daunorubicin and doxorubicin. Considering the potential use of several new alternative drug
delivery methods, such as intratumoural implantation of drug-impregnated polymers or liposomal
encapsulation of cytostatic drugs, daunorubicin and doxorubicin might be effective in the treatment of
malignant gliomas.
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Malignant gliomas, accounting for approximately one-half of
all primary brain tumours, remain incurable. The mean
survival time of patients with a malignant glioma is 8-12
months after standard treatment, consisting of surgical
resection and radiotherapy (Lesser and Grossman, 1994).
Most cytostatic drugs are ineffective in the treatment of
malignant gliomas. Treatment with 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) is considered to be the most effective
form of chemotherapy in the treatment of gliomas (Edwards
et al., 1980; Kornblith and Walker, 1988; Lesser and
Grossman, 1994). However, in controlled, randomised
studies no significant differences were found between glioma
patients receiving BCNU and radiotherapy vs radiotherapy
alone (Walker et al., 1978, 1980; Edwards et al., 1980;
Kornblith and Walker, 1988; Lesser and Grossman, 1994).
One of the major problems ofchemotherapy in the treatment
of brain tumours is the limited passage of most drugs
through the blood-brain barrier (BBB). Furthermore,
several biological mechanisms contribute to resistance to
chemotherapeutic agents, such as efficient DNA repair,
increased glutathione transferase activity, and overexpression
of P-glycoprotein (P-gp) or metallothionein (Deffie et al.,
1988; Bradley et al., 1988; Kelley et al., 1988). Resistance to
anthracyclins is often associated with overexpression of P-gp
(Bradley et al., 1988). Furthermore a gene coding for
multidrug resistance-related protein MRP has been isolated
and has recently also proved to be involved in resistance to
daunorubicin and doxorubicin (Cole et al., 1992, 1994).
Preclinical studies on the efficacy of cytostatic drugs for
gliomas are usually performed on cell lines or cell line-derived
spheroids. Using these culture models it appeared that several
drugs that are able to cross the BBB show a high cytolytic
activity in vitro, whereas glioma patients respond poorly to
these drugs (Yung et al., 1982; Kimmel et al., 1987; Yung
1989). Lack ofcellular heterogeneity in the cell lines used and
selection of themosensitive subpopulations during culture are
the most likely explanation for this discrepancy (Yung et al.,
1982; Kimmel et al., 1987; Westphal et al., 1988; Yung,
1989).
Surgically removed glioma tissue can be cultured as
organotypic multicellular spheroids (OMS), a culture model
in which the cellular heterogeneity and other characteristics
of the original tumour are preserved (Bjerkvig et al., 1990;
Kaaijk et al., 1995). Therefore, OMS represent the tumour in
vivo better than the frequently used cell line models.
In the present study, OMS prepared from malignant
gliomas were used to study the effects of daunorubicin and
doxorubicin. On the other hand, BCNU was also tested on
OMS, because BCNU is considered to be the most promising
agent in the treatment of glioma patients. After cytostatic
drugs treatment, the OMS were histologically evaluated and
cell proliferation was determined. To further analyse the
sensitivity for daunorubicin and doxorubicin the expression
of P-gp and MRP was examined immunohistochemically.
Materials and methods
Tumour tissues
Fresh glioma tissue was obtained during surgery from seven
patients: one astrocytoma grade II (s51), one oligodendro-
glioma (s52) and five glioblastomas multiforme (s50, s53, s54,
s55 and s59) as classified according to the WHO classification
(Kleihues et al., 1993). None of the patients had received
chemotherapy. A portion was fixed in formalin for diagnostic
purposes, a small portion of the tissue was frozen in liquid
nitrogen for immunohistochemical analysis, whereas the
remaining tissue was collected in Dulbecco's modification of
Eagle's medium (DMEM, Flow Laboratories, UK) for
preparation of OMS.
Culture of OMS
Brain tumour tissue was processed in the laboratory within
2 h after surgical resection. Forty-eight well plates (Becton
Dickinson, Mountain View, CA, USA) were coated with
0.1 ml of 0.75% agarose gel (Sigma, St Louis, MO, USA) in
culture medium, consisting of DMEM supplemented with
10% normal human serum [Central Laboratory of The
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Figure 1 OMS from tumour s53 exposed for 24h to (a) culture medium alone (control) (b) 200pgml-' BCNU (c) 10pgml-l
daunorubicin (d) 10jgml-l doxorubicin; immunostained for glial fibrillary acidic protein. OMS treated with daunorubicin and
doxorubicin were clearly more affected compared with the untreated OMS and the OMS treated with BCNU. Bar= 100,m.
Netherlands Red Cross Blood Transfusion Service (CLB),
Amsterdam, The Netherlands], 1 mM glutamine and
antibiotics (penicillin and streptomycin, both 100 IU ml-')
(all from Gibco, Paisley, UK). After the agarose dilution
had gelled, 0.3 ml of culture medium was added to each
well. For the preparation of the OMS, blood and necrotic
tissue were removed from tumour resection material and
fragments of 0.5-1 mm3 were dissected with sterile needles.
One fragment was transferred to each well of a 48-well
plate. The OMS were kept in a tissue culture incubator
(98% humidity, 95% air, 5% carbon dioxide) and the
medium was changed once a week. OMS were treated with
cytostatic drugs 1 -3 weeks after onset of OMS culture,
depending on the time point of the formation of round-
shaped spheroids. Five OMS per patient were used for each
cytostatic drug treatment.
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Cytostatic drugs exposure
The cytostatic drugs used in this study were 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) (Ben Venue Laboratories,
Bedford, OH, USA) and the two anthracyclins, i.e. daunor-
ubicin (Rhone-Poulenc Rorer, Amstelveen, The Netherlands)
and doxorubicin (Farmitalia Carlo Erba, Brussels, Belgium).
Daunorubicin and doxorubicin were dissolved in sterile
distilled water, whereas BCNU was dissolved in ethanol
before further dilution in sterile distilled water (as indicated
by the providers). The predetermined optimal and suboptimal
concentrations of the different drugs used in this study (data
Figure 2 H&E staining of OMS from tumour s59 exposed for 24h to (a) culture medium alone (control) (b) 200,ugml-' BCNU (c)
5 ggml-1 daunorubicin (d) 5Mgml-l doxorubicin; glial architecture of OMS treated with BCNU were still intact, whereas the glial
architecture of OMS treated with daunorubicin or doxorubicin is destroyed. In addition, increase ofcellular necrosis is visible after
daunorubicin and doxorubicin treatment. Bar=25im.
189Chemotherapy on glioma spheroids
P Kaaijk et al
not shown) were for daunorubicin and doxorubicin 2, 5, 10,
25 ig ml-' and for BCNU 2, 50, 100, 200 ,ug ml-l. OMS were
incubatedwithcytostatic drugs for24 h. After treatment, OMS
were washed several times in culture medium, and further
cultured for 48 h under standard culture conditions. Finally,
OMS were fixed in formalin and paraffin embedded.
Histology and immunohistochemistry
Paraffin sections stained with haematoxylin and eosin were
used to evaluate the histology of the OMS. Rabbit polyclonal
antibody against glial fibrillary acidic protein (GFAP;
Dakopatts, Glostrup, Denmark) was used to evaluate the
glial architecture. Monoclonal antibody, MIB-1 (Immuno-
tech, Marseille, France), reactive with the Ki-67 antigen, was
used to study cell proliferation. GFAP and Ki-67 immunos-
taining were performed on paraffin sections of the OMS. The
monoclonal antibodies JSB-1, MRK-16 and C219 were
kindly provided by Professor RJ Scheper and GL Scheffer
(Department of Pathology, Free University Hospital,
Amsterdam, The Netherlands) and were used to detect P-
glycoprotein (P-gp) (Scheper et al., 1988). Furthermore, a
monoclonal antibody reacting with the multidrug resistance-
related protein (MRP) was used. Immunostaining for P-gp
and MRP was performed on frozen sections of the resection
material from the gliomas that had been used for the
preparation of the OMS.
Paraffin sections (5 Mm) of OMS were placed on
organosilan-coated object slides and dried overnight at
37 'C. Sections were deparaffinised and endogenous perox-
idase activity was blocked with 0.3% hydrogen peroxide in
methanol. After incubation with monoclonal or polyclonal
antibody for 1 h at room temperature, sections were
incubated with respectively biotin-conjugated rabbit anti-
mouse immunoglobulins or biotin-conjugated swine anti-
rabbit immunoglobulins (both from Dakopatts). After
incubation with streptavidin-biotin complex (Dakopatts),
peroxidase activity was developed in 3,3-diamino-benzidine-
tetrachloride (Sigma) with 0.1% hydrogen peroxide. Sections
were counterstained with haematoxylin. Antigen retrieval was
necessary for Ki-67 immunostaining and was performed after
the endogenous peroxidase blocking step, by incubation in
citrate buffer (2.94 gl-' trisodium citrate dihydrate in distilled
water; pH6) at 100 'C for 20 min.
Cryostat sections were acetone fixed (5 Mm) and were
incubated with the different monoclonal antibodies for 1 h
at room temperature. Subsequently, endogenous peroxidase
was blocked with 0.3% hydrogen peroxidase in phos-
phate-buffered saline containing 0.1% sodium azide.
Thereafter, sections were incubated with biotin-conjugated
rabbit anti-mouse immunoglobulins. After incubation with
streptavidin-biotin complex, peroxidase activity was
developed in 3-amino-9-ethylcarbazole (Sigma) with
0.1 % hydrogen peroxide. Sections were counterstained
with haematoxylin.
Image analysis
The Ki-67 positive nuclei were quantified by computer-based
image analysis. Overview Images of OMS immunostained for
Ki-67 were acquired with a Sony CCD video camera
connected to the standard composite video input port of an
Apple Macintosh Quadra 840AV computer. Individual OMS
were assessed with image analysis software, using the public
domain 'NIH Image' program. A macro was developed that,
after background subtraction, counted all immunostained
nuclei above a predetermined density value. Subsequently, the
number of positive nuclei per mm2 was calculated. The
relative cell proliferation in the OMS from each tumour was
expressed as a percentage of the untreated control OMS
(100%) from that tumour.
Statistics
Statistical analysis of the data was performed using an
unpaired two sample t-test; P<0.03 was considered
significant.
Results
Approximately 70-90% of the tumour fragments from the
seven gliomas formed OMS. In OMS from all gliomas, with
the exception of tumour s52, a dense meshwork of GFAP
positive cells and fibrils was observed. In OMS from the
oligodendroglioma, s52, oligodendroglial components were
present. The presence of capillaries, connective tissue
components were common features in the OMS.
Figure 3 A dose-dependent increase in tissue damage to OMS was observed for the anthracyclins. H&E staining of OMS from
tumour s55 (a) untreated control OMS; and OMS exposed for 24h to doxorubicin at a concentration of: (b) 2,gml-1 (c) 5jugml-1
(d) l0jgmI-1. Bar=25ym.
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Figure 4 Effects of 24h exposure of the different cytostatic drugs on the cell proliferation in OMS from six gliomas. *Cell
proliferation in treated OMS differed significantly (with P<0.03) from cell proliferation in untreated control OMS.
Histology
The effects of 24 h exposure of BCNU, daunorubicin and
doxorubicin were studied 48 h after treatment on OMS
prepared from seven gliomas. All untreated control OMS
were completely viable without necrotic areas (Figures la and
2a). In general, the histological effects of the drugs were
found to be similar among OMS from different patients.
Histological damage caused by the different drugs started at
the periphery of the OMS for lower concentrations of the
drugs, but reached the centre of the OMS using increased
concentrations of the drugs.
BCNU did not induce histological damage to the OMS
(Figures lb and 2b). OMS that were treated with the highest
BCNU concentration of 200 pg ml-', showed few histologi-
cal changes: the glial architecture of the OMS remained intact
after treatment, and only a slight increase in cellular necrosis
(karyorrhexis with loss of the nuclear membrane and
disintegration of the nucleus into clumps of basophilic
material) was observed.
In contrast to BCNU, both daunorubicin and doxorubicin
induced severe histological damage to the OMS (Figures lc
and d and 2c and d), even at the lowest concentrations of 2-
5 pg ml-'. Applied at the same concentration, daunorubicin
was found to be slightly less effective in the induction of
tissue damage than doxorubicin. A dose-dependent increase
in histological damage could be observed at increasing
concentrations of both anthracyclins (Figure 3). The effects
varied from shrinkage of the volume of the OMS, retraction
of glial processes (which was clearly visualised with GFAP
immunostaining), increased cellular necrosis at the lowest
concentrations to almost completely necrotic OMS at higher
concentrations with loss of glial architecture, eosinophilic
cytoplasm and (micro)vacuolisation in the cytoplasm of the
glial tumour cells.
Cell proliferation
The effects of 24 h exposure of cytostatic drugs on cell
proliferation in the OMS was analysed 48 h after treatment
(Figure 4). The control OMS of the low-grade astrocytoma
(s51) showed 1% Ki-67-positive cells, the control OMS of the
oligodendroglioma (s52) had 10% Ki-67-positive cells and the
control OMS prepared from the glioblastomas (s50, s53, s54,
s55, s59) showed a Ki-67 positivity of respectively 3-5%,
2%, 2%, 6-7% and <1%. The number of Ki-67-positive
nuclei in OMS from tumour s59 was too low and tumour 59
was excluded from the study of cell proliferation. In all OMS
the cells that were Ki-67 positive were apparently vital, none
of the Ki-67-positive nuclei were condensed or fragmented.
The relative cell proliferation of all OMS did not change
significantly after BCNU exposure in the concentration range
of 25- 100 pg ml-', with one exception; the proliferation rate
in OMS from tumour s55 increased significantly (P<0.03)
after treatment with 50 pg ml-' BCNU. The proliferation
rates decreased significantly after 200 pg ml-1 BCNU
treatment (P<0.03) in OMS from four out of six gliomas.
In OMS from tumour s51, s52 and s55 the number of Ki-67-
positive tumour cells did not change significantly after
200 pg ml-1 BCNU exposure.
A significant decrease (P<0.03) in number of proliferating
cells was seen after incubation with daunorubicin and
doxorubicin in all OMS, with the exception of OMS from
tumour s55. In OMS from tumour s55, the number of Ki-67-
positive tumour cells did not change significantly after
exposure to 2, 5, 10 pg ml-' daunorubicin, and 2 pg ml- 1
doxorubicin, but a significant decrease of Ki-67-positive
tumour cells was seen after exposure to 5 or 10 ,g ml-
doxorubicin.
P-gp and MRP
In the resection material from all seven gliomas less than 5%
of the glial tumour cells were P-gp positive. Some capillaries
were positive for P-gp. All seven gliomas were completely
MRP negative.
Discussion
The efficacy of cytostatic drugs on gliomas in vitro is usually
tested on tumour cell lines or tumour cell line-derived
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spheroids. However, the often described high chemosensitiv-
ity of these glioma cell cultures does not correspond to the
poor response to chemotherapy seen in glioma patients. Lack
of cellular heterogeneity is probably an important factor that
contributes to this discrepancy: a cell line represents only a
small subpopulation of the original tumour owing to
selection during culture (Yung et al., 1982; Kimmel et al.,
1987; Wetphal et al., 1988; Yung, 1989).
The effects of cytostatic drugs on an alternative culture
model for gliomas, OMS, are described. OMS are more
representative of the in vivo situation, because in OMS the
original tumour structure, including the cellular heterogene-
ity, is preserved (Bjerkvig et al., 1990; Kaaijk et al., 1995).
Similar responses were observed to the various cytostatic
drugs for the different glioma types. We found that BCNU
induces only minor histological damage to OMS of human
gliomas. Even at a concentration of 200 pg ml-' BCNU,
which is approximately 100-fold of the maximal achievable
pharmacological concentration (Levin et al., 1978), no
obvious histological changes in the OMS were observed.
No significant changes in cell proliferation were observed
after 2-100 pg ml-' BCNU exposure with the exception of
OMS from one tumour that, surprisingly, showed a
significant increase in cell proliferation after 50 pg ml-'
BCNU treatment. The proliferation marker used in this
study recognises the Ki-67 antigen that is assumed to be
involved in DNA synthesis. Therefore up-regulation of Ki-67
might also be associated with DNA repair. This could explain
the increase in number of Ki-67-positive tumour cells after
BCNU treatment in this particular tumour. The proliferation
rates in OMS from four out of six gliomas treated with
200 pg ml-' BCNU decreased significantly.
These results are in agreement with other findings in the
literature that exposure of organ cultures of malignant
astrocytomas to BCNU does not result in microscopic
changes (Saez et al., 1977). Despite the fact that BCNU
crosses the BBB, BCNU is ineffective in the treatment of
glioma patients (Walker et al., 1978, 1980; Edwards et al.,
1980; Kornblith and Walker, 1988; Lesser and Grossman,
1994). Therefore, our results on OMS are in accordance with
this poor clinical response to BCNU. However, it is
noteworthy that the OMS were examined 48 h after BCNU
exposure. It might be that BCNU has more late effects rather
than acute effects on glioma tissue. In contrast to BCNU,
daunorubicin and doxorubicin induce severe tissue damage
and a significant decrease in cell proliferation, already found
at the lowest concentrations tested of 2-5 pg ml'-. Clinical
trials, however, revealed a poor response of glioma patients
to doxorubicin. In one of these studies it was shown that
doxorubicin did not reach cytotoxic levels in the glioma
tissue, owing to delivery problems (von Holst et al., 1990).
This explains the lack oftherapeutic response in these studies.
Overexpression of P-gp on tumour cells in vitro may lead
to resistance to a broad spectrum of unrelated cytostatic
drugs, including anthracyclins (Bradley et al., 1988). It has
been reported that glioma cells in situ hardly ever express P-
gp (Tanaka et al., 1994), which is in agreement with our
findings. In addition, we showed that all seven gliomas were
negative for MRP, which has also been found to be
associated with resistance to daunorubicin and doxorubicin
(Cole et al., 1994). Thus glioma cells may be sensitive for
daunorubicin and doxorubicin. The limited passage of
doxorubicin through the BBB might be an explanation for
the ineffectiveness of doxorubicin in glioma patients.
The present study shows that daunorubicin and doxo-
rubicin may be potent drugs for treating malignant gliomas,
when tumoricidal concentrations can be reached. This can be
accomplished by intratumoural administration of the drugs
or intratumoural implantation ofdrug-impregnated polymers
(Brem et al., 1991). Liposomal encapsulation of cytostatic
drugs is another alternative to circumvent the limited BBB
passage. Liposomal encapsulation of anthracyclins reduces
side-effects, and increases the delivery of the drugs to solid
tumours (Forssen et al., 1992). Besides this, new derivates of
daunorubicin have become available, which are more
lipophilic and more potent in killing glioma cells (Schott et
al., 1989).
In conventional in vitro drug testing assays with cell lines,
cell killing (as in radiolabelled precursor inhibition assays or
microcytotoxicty assays) or cell proliferation inhibition (as in
colony-forming assays) is measured (Kimmel et al., 1987). In
contrast, in OMS the histological cytotoxic effects of
cytostatic drugs, as well as the inhibition of cell prolifera-
tion, can be studied in one sample. Exposure of OMS to
cytostatic drugs appeared to be a reliable and simple method.
Hence, OMS are useful as a predictive test model for
individual patient's responses to several cytostatic drugs and
might have importance in screening new chemotherapeutic
agents for future clinical trials.
Ackwowklements
The authors thank Professor RJ Scheper and GL Scheffer
(Department of Pathology, Free University, Amsterdam, The
Netherlands) for kindly providing the monoclonal antibodies
against P-glycoprotein and the multidrug resistance-related
protein. We are grateful to Dr F van den Berg for his help in
developing a macro for the image analysis. The public domain
NIH Image program was written by Wayne Rasband at the US
National Institutes of Health and is available from the Internet by
anonymous ftp from zippy.ninh.nih.gov or on floppy disk from
NTIS, 5285 Port Royal Rd. Springfield, VA 22161 (part number
PB93-504868).
Refereces
BJERKVIG R, T0NNESEN A, LAERUM OD AND BACKLUND E-O.
(1990). Multicellular tumor spheroids from human gliomas
maintained in organ culture. J. Neurosurg., 72, 463-475.
BRADLEY G, JURANKA PF AND LING V. (1988). Mechanism of
multidrug resistance. Biochim. Biophys. Acta, 948, 87-128.
BREM H, MAHALEY SM, VICK NA, BLACK KL, SCHOLD SC,
BURGER PC, FRIEDMAN AH, CIRIC IS, ELLER TW, COZZENS
JW AND KENEALY JN. (1991). Interstitial chemotherapy with
drug polymer implants for the treatment ofrecurrent gliomas. J.
Neurosurg., 74, 441 -446.
COLE SPC, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE,
ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAB AMV AND
DEELEY RG. (1992). Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science, 258,
1650-1654.
COLE SPC, SPARKS KE, FRASER K, LOE DW, GRANT CE, WILSON
GM AND DEELEY RG. (1994). Pharmacological characterization
of multidrug resistant MRP-transfected human tumor cells.
Cancer Res., 54, 5902-5910.
DEFFIE AM, ALAM T, SENEVIRATNE C, BEENKEN SW, BATRA JK,
SHEA TC, HENNER WD AND GOLDENBERG GJ. (1988). Multi-
factorial resistance to adriamycin: relationship of DNA repair,
glutathione transferase activity, drugefflux, and P-glycoprotein in
cloned cell lines of adriamycin-sensitive and resistant P388
leukemia. Cancer Res., 43, 3595-3602.
EDWARDS MS, LEVIN VA AND WILSON CB. (1980). Brain tumor
chemotherapy: An evaluation ofagents in current use for phase I
and H trials. Cancer Treat. Rep., 64, 1179- 1204.
FORSSEN EA,COULTER DMANDPROFFITTRT. (1992). Selective in
vivo localization of daunorubicin small unilamellar vesicles in
solid tumors. Cancer Res., 52, 3255-61.
HOLST VON H, KNOCHENHAUER E, BLOMGREN H, COLLINS VP,
EHN L, LINDQUIST M, NOREN G AND PETERSON C. (1990).
Uptake ofadriamycin in tumour and surrounding brain tissue in
patients with malignant gliomas. Acta Neurochir., 104, 13-16.P Ka et x
193
KAAIJK P. TROOST D, DAS PK, LEENSTRA S AND BOSCH DA_
(1995). Long-term culture oforganotypic multicellular spheroids:
a good alternative for studying gliomas. Neuropathol. Appl.
Neurobiol., 21, 386-391.
KELLEY SL, BASU A, TEICHER BA, HACKER MP, HAMER DH AND
LAZO JS. (1988). Overexpression of metallothionein confers
resistance to anticancer drugs. Science, 241, 1813- 1815.
KIMMEL DW, SHAPIRO JRAND SHAPIRO WR (1987). In vitro drug
sensitivity testing in human gliomas. J. Neurosurg., CA, 161-171.
KLEIHUES P. BURGER PC AND SCHEITHAUER BW. (1993).
Histological typing of tumours of the central nervous system. In
World Health Organization International Histological Clasifica-
tion of Twnours, 2nd edn. Springer: Berlin.
KORNBLITH PL, AND WALKER M. (1988). Chemotherapy for
malignant gliomas. J. Neurosurg., 68, 1- 17.
LESSER GJ, AND GROSSMAN S. (1994). The chemotherapy ofhigh-
graded astrocytomas. Semin. Oncol., 21, 220-235.
LEVIN VA, HOFFMAN AND WEINKAM RJ. (1978). Pharmocoki-
netics of BCNU in man: a preliminary study of 20 patients.
Cancer Treat. Rep., 62, 1305- 1312.
SAEZ RJ, CAMPBELL RJ AND LAWS ER (1977). Chemotherapeutic
trials in human malignant astrocytomas in organ culture. J.
Neurosurg., 46, 320-327.
SCHEPER RJ, BULTE JWM, BRAKKEE JGM, QUAK JJ, VAN DER
SCHOOT E, BALM AIM, MEIJER CILM, BROXTERMAN HJ,
KUIPER CM, LANKELMA J AND PINEDO HM. (1988). Mono-
clonal antibodyJSB-1 detects ahighlyconservedepitopeon theP-
glycoprotein associated with multidrug-resistance. Int. J. Cancer,
42, 389-394.
SCHOTT B AND ROBERT J. (1989). Comparative cytotoxicity, DNA
synthesis inhibition and drug incorporation of eight anthracy-
clines in a model of doxorubicin-sensitive and -resistant rat
glioblastoma cells. Biochem. Pharmacol., 38, 167-72.
TANAKA Y, ABE Y, TSUGU A, TAKAMIYA Y, AKATSUKA A,
TSURUO T, YAMAKAZI H, UEYAMA Y, SATO 0, TAMAOKI N
ANDNAKAMURA M. (1994). Ultrastructural localization of P-
glycoprotein on capillary endothelial cells in human gilomas.
Virch. Arch., 425, 133-138.
WALKER MD, ALEXANDER E, HUNT WE, MACCARTY CS,
MAHALEY MS, MEALEY J, NORRELL HA, OWENS G, RANSOH-
OFF J, WILSON CB, GEHAN EA, AND STRIKE TA. (1978).
Evaluation of BCNU and/or radiotherapy in the treatment of
anaplastic gliomas. J. Neurosurg., 49, 333-343.
WALKER MD, GREEN SB, BYAR DP, ALEXANDER E, BATZDORF U,
BROOKS WH, HUNT WE, MACCARTY CS, MAHALEY MA,
MEALEY J, OWENS G, RANSOHOFF J, ROBERTSON IT, SHAPIRO
WR, SMITH KR, WILSON CB AND STRIKE TA. (1980).
Randomized comparisons of radiotherapy and nitrosoureas for
the treatment of malignant gliomas after surgery. N. Engi. J.
Med., 363, 1323-1329.
WESTPHAL M, HANSEL M,NAUSCH H, ROHDE E, KOPPEN J, FIOLA
R, HOLZEN F AND HERRMANN H-D. (1988). Glioma biology in
vitro: goals and concepts. Acta Neurochir., 43 (suppl.), 107- 113.
YUNGWKA. (1989). In vitro chemosensitivity testing and its clinical
application in human gliomas. Neurosurg. Rev., 12, 197-203.
YUNG WKA, SHAPIRO JR AND SHAPIRO WR_ (1982). Hetero-
geneous chemosensitivities of subpopulations of human glioma
cells in culture. Cancer Res., 42, 992-998.